Patents by Inventor Reinhard Bolli
Reinhard Bolli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11723953Abstract: A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.Type: GrantFiled: July 6, 2021Date of Patent: August 15, 2023Assignee: CSL LimitedInventors: Samuel Wright, Martin Imboden, Reinhard Bolli, Marcel Waelchli
-
Publication number: 20220133852Abstract: A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.Type: ApplicationFiled: July 6, 2021Publication date: May 5, 2022Applicant: CSL LimitedInventors: Samuel Wright, Martin Imboden, Reinhard Bolli, Marcel Waelchli
-
Patent number: 11058747Abstract: A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.Type: GrantFiled: June 19, 2019Date of Patent: July 13, 2021Assignee: CSL LIMITEDInventors: Samuel Wright, Martin Imboden, Reinhard Bolli, Marcel Waelchli
-
Publication number: 20200171126Abstract: A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.Type: ApplicationFiled: June 19, 2019Publication date: June 4, 2020Applicant: CSL LimitedInventors: Samuel Wright, Martin Imboden, Reinhard Bolli, Marcel Waelchli
-
Patent number: 10335457Abstract: A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.Type: GrantFiled: August 19, 2016Date of Patent: July 2, 2019Assignee: CSL LIMITEDInventors: Samuel Wright, Martin Imboden, Reinhard Bolli, Marcel Waelchli
-
Publication number: 20170196935Abstract: A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.Type: ApplicationFiled: August 19, 2016Publication date: July 13, 2017Inventors: Samuel Wright, Martin Imboden, Reinhard Bolli, Marcel Waelchli
-
Patent number: 9439946Abstract: A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.Type: GrantFiled: February 27, 2015Date of Patent: September 13, 2016Assignee: CSL LIMITEDInventors: Samuel Wright, Martin Imboden, Reinhard Bolli, Marcel Waelchli
-
Publication number: 20160022768Abstract: A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.Type: ApplicationFiled: February 27, 2015Publication date: January 28, 2016Applicant: CSL LimitedInventors: Samuel Wright, Martin Imboden, Reinhard Bolli, Marcel Waelchli
-
Patent number: 8999920Abstract: A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.Type: GrantFiled: June 30, 2011Date of Patent: April 7, 2015Assignee: CSL LimitedInventors: Samuel Wright, Martin Imboden, Reinhard Bolli, Marcel Waelchli
-
Patent number: 8962802Abstract: This invention relates to protein separation and purification methods for both alpha-1-antitrypsin (AAT, also known as alpha-1 proteinase inhibitor, API, and A.sub.1-PI) and Apolipoprotein A-I (ApoA-1) from, for example, a fraction of human blood plasma. In certain embodiments, the invention provides methods for separating AAT from ApoA-1 at the initial stage of purification, so that the same starting material can be used as a source for both proteins. The methods further pertain to providing compositions of AAT and of ApoA-1 suitable for pharmaceutical use and are suitable for large-scale purification.Type: GrantFiled: December 3, 2013Date of Patent: February 24, 2015Assignee: CSL Behring GmbHInventors: Nathan Brinkman, Douglas Bigler, Reinhard Bolli, Vreni Foertsch
-
Patent number: 8906368Abstract: The present invention relates to a protein preparation having increased stability, comprising a stabilizer selected from the group consisting of non-polar and basic amino acids and having a pH of 4.0 to 5.2. The invention further relates to a pharmaceutical composition and a method of stabilizing protein preparations.Type: GrantFiled: September 14, 2012Date of Patent: December 9, 2014Assignee: ZLB Behring AGInventors: Reinhard Bolli, Gerhard Hodler, Regula Styger
-
Patent number: 8715652Abstract: The present invention relates to a protein preparation having increased stability, comprising a stabiliser selected from the group consisting of non-polar and basic amino acids and having a pH of 4.0 to 5.2. The invention further relates to a pharmaceutical composition and a method of stabilising protein preparations.Type: GrantFiled: November 17, 2004Date of Patent: May 6, 2014Assignee: CSL Behring AGInventors: Reinhard Bolli, Gerhard Hodler, Regula Styger
-
Publication number: 20140094591Abstract: This invention relates to protein separation and purification methods for both alpha-1-antitrypsin (AAT, also known as alpha-1 proteinase inhibitor, API, and A.sub.1-PI) and Apolipoprotein A-I (ApoA-1) from, for example, a fraction of human blood plasma. In certain embodiments, the invention provides methods for separating AAT from ApoA-1 at the initial stage of purification, so that the same starting material can be used as a source for both proteins. The methods further pertain to providing compositions of AAT and of ApoA-1 suitable for pharmaceutical use and are suitable for large-scale purification.Type: ApplicationFiled: December 3, 2013Publication date: April 3, 2014Applicant: CSL Behring GmbHInventors: Nathan Brinkman, Douglas Bigler, Reinhard Bolli, Vreni Foertsch
-
Patent number: 8653245Abstract: This invention relates to protein separation and purification methods for both alpha-1-antitrypsin (AAT, also known as alpha-1 proteinase inhibitor, API, and A.sub.1-PI) and Apolipoprotein A-I (ApoA-1) from, for example, a fraction of human blood plasma. In certain embodiments, the invention provides methods for separating AAT from ApoA-1 at the initial stage of purification, so that the same starting material can be used as a source for both proteins. The methods further pertain to providing compositions of AAT and of ApoA-1 suitable for pharmaceutical use and are suitable for large-scale purification.Type: GrantFiled: April 5, 2013Date of Patent: February 18, 2014Assignee: CSL Behring GmbHInventors: Nathan Brinkman, Douglas Bigler, Reinhard Bolli, Vreni Foertsch
-
Publication number: 20130190226Abstract: A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.Type: ApplicationFiled: June 30, 2011Publication date: July 25, 2013Inventors: Samuel Wright, Martin Imboden, Reinhard Bolli, Marcel Waelchli
-
Patent number: 8436152Abstract: This invention relates to protein separation and purification methods for both alpha-1-antitrypsin (AAT, also known as alpha-1 proteinase inhibitor, API, and A1-PI) and Apolipoprotein A-I (ApoA-I) from, for example, a fraction of human blood plasma. In certain embodiments, the invention provides methods for separating AAT from ApoA-I at the initial stage of purification, so that the same starting material can be used as a source for both proteins. The methods further pertain to providing compositions of AAT and of ApoA-I suitable for pharmaceutical use and are suitable for large-scale purification.Type: GrantFiled: August 15, 2008Date of Patent: May 7, 2013Assignee: CSL Behring GmbHInventors: Nathan Brinkman, Douglas Bigler, Reinhard Bolli, Vreni Foertsch
-
Publication number: 20130102760Abstract: The present invention relates to a protein preparation having increased stability, comprising a stabiliser selected from the group consisting of non-polar and basic amino acids and having a pH of 4.0 to 5.2. The invention further relates to a pharmaceutical composition and a method of stabilising protein preparations.Type: ApplicationFiled: September 14, 2012Publication date: April 25, 2013Inventors: Reinhard BOLLI, Gerhard Hodler, Regula Styger
-
Publication number: 20110087008Abstract: This invention relates to protein separation and purification methods for both alpha-1-antitrypsin (AAT, also known as alpha-1 proteinase inhibitor, API, and A1-PI) and Apolipoprotein A-I (ApoA-1) from, for example, a fraction of human blood plasma. In certain embodiments, the invention provides methods for separating AAT from ApoA-1 at the initial stage of purification, so that the same starting material can be used as a source for both proteins. The methods further pertain to providing compositions of AAT and of ApoA-1 suitable for pharmaceutical use and are suitable for large-scale purification.Type: ApplicationFiled: August 15, 2008Publication date: April 14, 2011Inventors: Nathan Brinkman, Douglas Bigler, Reinhard Bolli, Vreni Foertsch
-
Publication number: 20070122402Abstract: The present invention relates to a protein preparation having increased stability, comprising a stabiliser selected from the group consisting of non-polar and basic amino acids and having a pH of 4.0 to 5.2. The invention further relates to a pharmaceutical composition and a method of stabilising protein preparations.Type: ApplicationFiled: November 17, 2004Publication date: May 31, 2007Inventors: Reinhard Bolli, Gerhard Hodler, Regula Styger